YU6799A - Derivati tetrahidrohinolina kao antagonisti eaa - Google Patents

Derivati tetrahidrohinolina kao antagonisti eaa

Info

Publication number
YU6799A
YU6799A YU6799A YU6799A YU6799A YU 6799 A YU6799 A YU 6799A YU 6799 A YU6799 A YU 6799A YU 6799 A YU6799 A YU 6799A YU 6799 A YU6799 A YU 6799A
Authority
YU
Yugoslavia
Prior art keywords
group
alkoxy
hydrogen
integer
amino
Prior art date
Application number
YU6799A
Other languages
English (en)
Inventor
Romano Di-Fabio
Alessandra Pasquarello
Fabio Maria Sabbatini
Original Assignee
Glaxo Wellcome S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome S.P.A. filed Critical Glaxo Wellcome S.P.A.
Publication of YU6799A publication Critical patent/YU6799A/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Jedinjenja formule (I) ili njihova so ili metabolički labilan estar, u kojima R predstavlja grupu koja se bira izmedju halogen, alakil, alkoksi, amino, alkilamino, dialkilamino, hidroksi, trifluorometil, trifluorometoksi, nitro, cijano, SO2R2 ili COR2, gde R2 predstavlja hidroksi, metoksi, amino, alkilamino ili dialkilamino; m je nula ili ceo broj 1 ili 2; R1 predstavlja grrupu (CH2)nCN, -CH=CHR3, (CH2)nNHCOCH2R4 ili O(CH2)pNR5R6; R3 predstavlja cijano ili COR7 grupu; R4 predstavlja alkoksi ili NHCOR8 grupu; R5 i R6 predstavljaju, svaki nezavisno, vodonik ili alkil, ili R5 i R6, zajedno sa atomom azota za koji su vezani, predstavljaju h eterocikličnu grupu, ili je R5 vodonik, a R6 grupa COR9; R7 predstavlja alkoksi, amino ili hidroksilnu grupu; R8 predstavlja atom vodonika ili opciono supstituisanu alkil, alkoksi, aril ili heterocikličnu grupu; R9 je grupa R8, ili grupa NR10R11, u kojoj R10 predstavlja vodonik ili alkil grupu; R11 predstavlja opciono supstituisanu alkil, aril, heterocikličnu ili cikloalkil grupu; n je nula ili ceo broj od 1 do 4; i p je ceo broj od 2 do 4, postupke njihovog dobijanja i njihovu upotrebu u medicini.
YU6799A 1996-08-17 1997-08-14 Derivati tetrahidrohinolina kao antagonisti eaa YU6799A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9617305.9A GB9617305D0 (en) 1996-08-17 1996-08-17 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
YU6799A true YU6799A (sh) 2000-03-21

Family

ID=10798623

Family Applications (1)

Application Number Title Priority Date Filing Date
YU6799A YU6799A (sh) 1996-08-17 1997-08-14 Derivati tetrahidrohinolina kao antagonisti eaa

Country Status (34)

Country Link
US (1) US6479488B1 (sh)
EP (1) EP0922034B1 (sh)
JP (1) JP4108129B2 (sh)
KR (1) KR100552864B1 (sh)
CN (1) CN1131214C (sh)
AP (1) AP877A (sh)
AR (1) AR008296A1 (sh)
AT (1) ATE221052T1 (sh)
AU (1) AU724473B2 (sh)
BR (1) BR9711311B1 (sh)
CA (1) CA2264118C (sh)
CO (1) CO4900066A1 (sh)
CZ (1) CZ296250B6 (sh)
DE (1) DE69714265T2 (sh)
DK (1) DK0922034T3 (sh)
EA (1) EA001704B1 (sh)
ES (1) ES2181030T3 (sh)
GB (1) GB9617305D0 (sh)
HU (1) HU225797B1 (sh)
ID (1) ID18095A (sh)
IL (1) IL128141A0 (sh)
IS (1) IS4953A (sh)
MY (1) MY116952A (sh)
NO (1) NO312241B1 (sh)
NZ (1) NZ333812A (sh)
PE (1) PE107098A1 (sh)
PL (1) PL194532B1 (sh)
PT (1) PT922034E (sh)
SI (1) SI0922034T1 (sh)
TR (1) TR199900336T2 (sh)
TW (1) TW449582B (sh)
WO (1) WO1998007704A1 (sh)
YU (1) YU6799A (sh)
ZA (1) ZA977326B (sh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706294D0 (en) * 1997-03-26 1997-05-14 Glaxo Wellcome Spa Heterocyclic compound
MY125037A (en) 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
US6455734B1 (en) 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
GB9929037D0 (en) 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
DE10132725A1 (de) 2001-07-05 2006-08-03 Grünenthal GmbH Substituierte γ-Lactonverbindungen
IL162616A0 (en) * 2001-12-28 2005-11-20 Acadia Pharm Inc Tetrahydroquinoline analogues as muscarinic agonists
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
JP2006515628A (ja) * 2003-01-23 2006-06-01 アカディア ファーマシューティカルズ,インコーポレーテッド ヒト神経精神疾患を処置するためのn−デスメチルクロザピンの使用
WO2004073639A2 (en) * 2003-02-19 2004-09-02 Merck & Co. Inc. Treatment of psychosis with a muscarinic m1 receptor ectopic activator
SG133606A1 (en) * 2003-12-22 2007-07-30 Acadia Pharm Inc Amino substituted diaryl [a,d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
CA2560671A1 (en) * 2004-04-01 2006-01-05 Acadia Pharmaceuticals Inc. Crystalline forms of n-desmethylclozapine
PT1908753E (pt) * 2005-07-22 2015-02-06 Mochida Pharm Co Ltd Novo derivado acetamida de heterociclideno
RU2451014C2 (ru) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
US8480797B2 (en) 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
WO2007033082A2 (en) * 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (dmso)
CA2622204C (en) 2005-09-12 2016-10-11 Abela Pharmaceuticals, Inc. Systems for removing dimethyl sulfoxide (dmso) or related compounds, or odors associated with same
US20070105836A1 (en) * 2005-10-31 2007-05-10 Lars Pettersson Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
BRPI0921494A2 (pt) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
JP5947721B2 (ja) 2009-10-30 2016-07-06 アベラ ファーマスーティカルズ インコーポレイテッド 変形性関節症を治療するためのジメチルスルホキシド(dmso)およびメチルスルホニルメタン(msm)製剤
CA2850707C (en) 2011-10-03 2023-03-21 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE147732T1 (de) * 1989-03-08 1997-02-15 Merck Sharp & Dohme Tetrahydroquinolin-derivate, verwendbar bei neurodegenerativen krankheiten
PL186781B1 (pl) 1995-09-29 2004-02-27 Glaxo Wellcome Spa Nowy związek, pochodna tetrahydrochinoliny, sposób wytwarzania pochodnej tetrahydrochinoliny, środek farmaceutyczny i zastosowanie

Also Published As

Publication number Publication date
CZ296250B6 (cs) 2006-02-15
DK0922034T3 (da) 2002-11-18
PL194532B1 (pl) 2007-06-29
EA001704B1 (ru) 2001-06-25
NO990723D0 (no) 1999-02-16
DE69714265T2 (de) 2003-03-06
KR100552864B1 (ko) 2006-02-20
US6479488B1 (en) 2002-11-12
EA199900121A1 (ru) 1999-10-28
TW449582B (en) 2001-08-11
TR199900336T2 (xx) 1999-04-21
JP2001508031A (ja) 2001-06-19
NO312241B1 (no) 2002-04-15
CO4900066A1 (es) 2000-03-27
HUP9903108A3 (en) 2004-04-28
ZA977326B (en) 1999-02-15
BR9711311A (pt) 1999-08-17
KR20000068172A (ko) 2000-11-25
EP0922034B1 (en) 2002-07-24
NZ333812A (en) 2000-07-28
CA2264118C (en) 2008-06-17
AR008296A1 (es) 1999-12-29
SI0922034T1 (en) 2003-02-28
CN1131214C (zh) 2003-12-17
DE69714265D1 (de) 2002-08-29
GB9617305D0 (en) 1996-09-25
BR9711311B1 (pt) 2009-01-13
PT922034E (pt) 2002-12-31
CN1227544A (zh) 1999-09-01
AU724473B2 (en) 2000-09-21
AP877A (en) 2000-09-27
CA2264118A1 (en) 1998-02-26
AP9901459A0 (en) 1999-03-31
JP4108129B2 (ja) 2008-06-25
ES2181030T3 (es) 2003-02-16
HU225797B1 (en) 2007-09-28
NO990723L (no) 1999-04-14
ID18095A (id) 1998-02-26
IS4953A (is) 1999-01-22
PE107098A1 (es) 1999-01-15
WO1998007704A1 (en) 1998-02-26
PL331562A1 (en) 1999-07-19
ATE221052T1 (de) 2002-08-15
IL128141A0 (en) 1999-11-30
AU4551897A (en) 1998-03-06
EP0922034A1 (en) 1999-06-16
MY116952A (en) 2004-04-30
CZ52999A3 (cs) 1999-07-14

Similar Documents

Publication Publication Date Title
YU6799A (sh) Derivati tetrahidrohinolina kao antagonisti eaa
TW200643015A (en) 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
SE9301241L (sv) Indolderivat
DK1092716T3 (da) Benzothiophenderivater, benzofuranderivater og indolderivater, fremgangsmåde til fremstilling heraf og farmaceutiske tilberedninger indeholdende disse
MY129540A (en) Quinazoline derivatives, pharmaceutical compositions containing them processes for their preparation and their use in the production of an antiangiogenic and/or vascular permeability reducing effect
AR051638A1 (es) Compuestos de piperidinilo y su uso para tratar desordenes de respuesta al bloqueo de los canales de calcio tipo n
AR036042A1 (es) Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa
ATE226189T1 (de) Saure gruppen enthaltende phenylderivate, ihre herstellung und ihre verwendung als chloridkanalblocker
DE69330351T2 (de) 5-arylindol-derivate und ihre verwendung als serotonin (5-ht1)-agonisten
DE69810958D1 (de) Harnstoffderivate und ihre anwendung als integrin-inhibitoren
AR005233A1 (es) Derivados de 1,2,3,4-tetrahidroquinolina, procesos para su preparacion, una composicion farmaceutica y el uso en la elaboracion de un medicamento
CO4700452A1 (es) Derivados de indol
AR028648A1 (es) Derivados de 1,4-diazabiciclo[3.2.2]nonano-fenilisoxazol, su preparacion y su aplicacion en terapéutica
FR2674849B1 (fr) Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique.
SE9703378D0 (sv) New compounds
ATE199543T1 (de) Bibphenylamid-derivate als 5-ht1d-antagonisten
DK0461958T3 (da) 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxanderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i terapien
EP0351255A3 (en) Derivatives of û2-(4-piperidinyl)methyl¨-1,2,3,4-tetrahydroisoquinoline, their preparation and their use in therapy
YU196990A (sh) Herbicidi derivati 2-azolil-nikotinata
KR860000286A (ko) 디히드로피리딘 유도체의 제조방법
KR910007928A (ko) 신규 벤조[1,8] 나프티리딘 유도체, 그의 제조 및 그를 함유하는 조성물
AP9400638A0 (en) Water soluble derivatives of camptothecin.
EP0315434A3 (en) Pyridoxal hydrazone derivatives their production and use and pharmaceutical compositions containing the same
ATE119523T1 (de) Isochinolinderivate und ihre salze als proteasehemmer.
RU2006141096A (ru) Моноциклические гетероциклы, ингибирующие киназу